Brief: Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
21/05/2024 13:19
May 21 (Reuters) - Alvotech SA ALVO.O :
* ALVOTECH AND DR. REDDY’S ENTER INTO COLLABORATION FOR
COMMERCIALIZATION OF AVT03 (DENOSUMAB), A BIOSIMILAR CANDIDATE
TO PROLIA® & XGEVA® IN THE U.S., EUROPE AND UK
* ALVOTECH SA - ALVOTECH WILL BE RESPONSIBLE FOR DEVELOPMENT
AND
MANUFACTURING OF PRODUCT
* ALVOTECH SA - DR. REDDY'S WILL BE RESPONSIBLE FOR
REGISTRATION
AND COMMERCIALIZATION OF PRODUCT IN APPLICABLE MARKETS
Source text for Eikon: ID:nGNX1Cd2Hm
Further company coverage: ALVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alvotech SA
See all newsBrief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Brief: Alvotech and Teva Secure U.S. Settlement Date For AVT06
India's Dr Reddy's rises after EU marketing authorisation for osteoporosis biosimilar
Brief: UK High Court Rules In Favor Of Alvotech Paving Way For AVT06, Biosimilar To Eylea
U.S. STOCKS ON THE MOVE-Cummins, EPAM Systems, Qualcomm